Elo Mutual Pension Insurance Co Has $5.45 Million Stock Holdings in McKesson Co. (NYSE:MCK)

Elo Mutual Pension Insurance Co grew its position in shares of McKesson Co. (NYSE:MCKFree Report) by 3.8% during the fourth quarter, HoldingsChannel.com reports. The firm owned 11,778 shares of the company’s stock after purchasing an additional 436 shares during the period. Elo Mutual Pension Insurance Co’s holdings in McKesson were worth $5,453,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Douglass Winthrop Advisors LLC lifted its stake in shares of McKesson by 1.4% in the fourth quarter. Douglass Winthrop Advisors LLC now owns 1,512 shares of the company’s stock worth $700,000 after acquiring an additional 21 shares during the period. Addison Advisors LLC lifted its stake in shares of McKesson by 7.9% in the fourth quarter. Addison Advisors LLC now owns 299 shares of the company’s stock worth $138,000 after acquiring an additional 22 shares during the period. Evergreen Wealth Solutions LLC lifted its stake in shares of McKesson by 1.2% in the fourth quarter. Evergreen Wealth Solutions LLC now owns 1,931 shares of the company’s stock worth $894,000 after acquiring an additional 22 shares during the period. Keystone Financial Services lifted its stake in shares of McKesson by 2.1% in the fourth quarter. Keystone Financial Services now owns 1,192 shares of the company’s stock worth $552,000 after acquiring an additional 24 shares during the period. Finally, Carolinas Wealth Consulting LLC lifted its stake in shares of McKesson by 42.9% in the fourth quarter. Carolinas Wealth Consulting LLC now owns 80 shares of the company’s stock worth $37,000 after acquiring an additional 24 shares during the period. 85.07% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MCK has been the subject of a number of research analyst reports. Leerink Partnrs reiterated an “outperform” rating on shares of McKesson in a report on Monday, February 26th. Morgan Stanley lifted their target price on McKesson from $522.00 to $548.00 and gave the stock an “overweight” rating in a report on Monday, April 15th. UBS Group lifted their target price on McKesson from $620.00 to $630.00 and gave the stock a “buy” rating in a report on Wednesday, May 8th. Barclays lifted their target price on McKesson from $571.00 to $596.00 and gave the stock an “overweight” rating in a report on Wednesday, May 8th. Finally, Wells Fargo & Company lifted their target price on McKesson from $502.00 to $551.00 and gave the stock an “equal weight” rating in a report on Thursday, May 9th. Two investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, McKesson has a consensus rating of “Moderate Buy” and an average target price of $571.47.

View Our Latest Stock Report on McKesson

Insider Activity

In other news, CEO Brian S. Tyler sold 3,473 shares of the firm’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $524.55, for a total transaction of $1,821,762.15. Following the completion of the sale, the chief executive officer now directly owns 43,445 shares of the company’s stock, valued at approximately $22,789,074.75. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other McKesson news, CEO Brian S. Tyler sold 3,473 shares of the company’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $524.55, for a total transaction of $1,821,762.15. Following the sale, the chief executive officer now directly owns 43,445 shares of the company’s stock, valued at $22,789,074.75. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Brian S. Tyler sold 3,753 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $574.41, for a total transaction of $2,155,760.73. Following the completion of the sale, the chief executive officer now directly owns 89,845 shares in the company, valued at approximately $51,607,866.45. The disclosure for this sale can be found here. Insiders sold a total of 28,204 shares of company stock valued at $15,699,113 in the last ninety days. 0.21% of the stock is currently owned by insiders.

McKesson Trading Down 0.2 %

McKesson stock traded down $1.10 during trading on Monday, hitting $585.80. 70,154 shares of the company were exchanged, compared to its average volume of 709,544. The business’s 50 day moving average is $545.73 and its 200 day moving average is $511.14. McKesson Co. has a 52 week low of $389.48 and a 52 week high of $591.80. The company has a market capitalization of $76.15 billion, a P/E ratio of 26.16, a PEG ratio of 1.37 and a beta of 0.47.

McKesson (NYSE:MCKGet Free Report) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $6.18 earnings per share for the quarter, missing the consensus estimate of $6.34 by ($0.16). McKesson had a negative return on equity of 245.88% and a net margin of 0.97%. The business had revenue of $76.36 billion during the quarter, compared to analysts’ expectations of $79.32 billion. During the same period in the prior year, the firm posted $7.19 EPS. The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. Equities analysts expect that McKesson Co. will post 31.54 EPS for the current year.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 1st. Stockholders of record on Monday, June 3rd will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 0.42%. The ex-dividend date is Monday, June 3rd. McKesson’s dividend payout ratio is presently 11.08%.

McKesson Profile

(Free Report)

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

Further Reading

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCKFree Report).

Institutional Ownership by Quarter for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.